Price E, Gesquiere A
Sci Adv. 2020; 6(4):eaax2642.
PMID: 32076633
PMC: 7002136.
DOI: 10.1126/sciadv.aax2642.
Niederalt C, Kuepfer L, Solodenko J, Eissing T, Siegmund H, Block M
J Pharmacokinet Pharmacodyn. 2017; 45(2):235-257.
PMID: 29234936
PMC: 5845054.
DOI: 10.1007/s10928-017-9559-4.
Eigenmann M, Fronton L, Grimm H, Otteneder M, Krippendorff B
MAbs. 2017; 9(6):1007-1015.
PMID: 28613103
PMC: 5540074.
DOI: 10.1080/19420862.2017.1337619.
Peters C, Brown S
Biosci Rep. 2015; 35(4).
PMID: 26182432
PMC: 4613712.
DOI: 10.1042/BSR20150089.
Masson Hinrichs M, Dixit R
AAPS J. 2015; 17(5):1055-64.
PMID: 26024656
PMC: 4540738.
DOI: 10.1208/s12248-015-9790-0.
Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Marquez B, Ikotun O, Zheleznyak A, Wright B, Hari-Raj A, Pierce R
Mol Pharm. 2014; 11(11):3988-95.
PMID: 25058168
PMC: 4224522.
DOI: 10.1021/mp500323d.
Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.
Yip V, Palma E, Tesar D, Mundo E, Bumbaca D, Torres E
MAbs. 2014; 6(3):689-96.
PMID: 24572100
PMC: 4011913.
DOI: 10.4161/mabs.28254.
Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
Smith M, Reardon J, Olson E
Drugs Today (Barc). 2012; 48(11):713-22.
PMID: 23170307
PMC: 3786342.
DOI: 10.1358/dot.2012.48.11.1885879.
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A, Balthasar J
J Pharmacokinet Pharmacodyn. 2007; 34(5):687-709.
PMID: 17636457
DOI: 10.1007/s10928-007-9065-1.
Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.
Gutierrez J, Leon G, Lomonte B
Clin Pharmacokinet. 2003; 42(8):721-41.
PMID: 12846594
DOI: 10.2165/00003088-200342080-00002.
Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.
Junghans R
Immunol Res. 1997; 16(1):29-57.
PMID: 9048207
DOI: 10.1007/BF02786322.
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.
Israel E, Wilsker D, Hayes K, Schoenfeld D, Simister N
Immunology. 1996; 89(4):573-8.
PMID: 9014824
PMC: 1456584.
DOI: 10.1046/j.1365-2567.1996.d01-775.x.
Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.
Junghans R, Waldmann T
J Exp Med. 1996; 183(4):1587-602.
PMID: 8666917
PMC: 2192498.
DOI: 10.1084/jem.183.4.1587.
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
Junghans R, Anderson C
Proc Natl Acad Sci U S A. 1996; 93(11):5512-6.
PMID: 8643606
PMC: 39277.
DOI: 10.1073/pnas.93.11.5512.
Catabolism of hirudin and thrombin-hirudin complexes in the rat.
Bichler J, Baynes J, Thorpe S
Biochem J. 1993; 296 ( Pt 3):771-6.
PMID: 8280076
PMC: 1137762.
DOI: 10.1042/bj2960771.
Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice.
Talbot P, Buchmeier M
Immunology. 1987; 60(4):485-9.
PMID: 3034767
PMC: 1453269.
Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography.
Demignot S, Pimm M, Thorpe S, Baldwin R
Cancer Immunol Immunother. 1991; 33(6):359-66.
PMID: 1878889
PMC: 11038862.
DOI: 10.1007/BF01741595.
A fluorescent residualizing label for studies on protein uptake and catabolism in vivo and in vitro.
Maxwell J, Terracio L, Borg T, Baynes J, Thorpe S
Biochem J. 1990; 267(1):155-62.
PMID: 1691636
PMC: 1131258.
DOI: 10.1042/bj2670155.
Antibody-secreting cell responses in the mouse liver.
Wu H, Russell M
Immunology. 1992; 77(3):443-8.
PMID: 1478688
PMC: 1421704.
